Clinical trial
Radiomics for the Prediction of Survival in GBM After Radiotherapy With/Without Temozolomide
NCT02666066 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Radiomics for the Prediction of Survival in GBM After Radiotherapy With/Without Temozolomide
- Lead sponsor
- Maastricht Radiation Oncology
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- July 31, 2018
- Enrollment
- 289 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.